ARCUTIS BIOTHERAPEUTICS, INC. FDA Approval NDA 215985

NDA 215985

ARCUTIS BIOTHERAPEUTICS, INC.

FDA Drug Application

Application #215985

Documents

Letter2022-08-01
Label2022-08-01

Application Sponsors

NDA 215985ARCUTIS BIOTHERAPEUTICS, INC.

Marketing Status

Prescription001

Application Products

001CREAM;TOPICAL0.3%0ZORYVEROFUMILAST

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2022-07-29STANDARD

Submissions Property Types

ORIG1Null40

CDER Filings

ARCUTIS BIOTHERAPEUTICS, INC.
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 215985
            [companyName] => ARCUTIS BIOTHERAPEUTICS, INC.
            [docInserts] => ["",""]
            [products] => [{"drugName":"ZORYVE","activeIngredients":"ROFUMILAST","strength":"0.3%","dosageForm":"CREAM;TOPICAL","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
            [labels] => [{"actionDate":"07\/29\/2022","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215985s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"07\/29\/2022","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215985s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/215985Orig1s000ltr.pdf\"}]","notes":">"}]
            [supplements] => 
            [actionDate] => 2022-07-29
        )

)

© 2022 FDA.report
This site is not affiliated with or endorsed by the FDA.